Form no

Call for transnational research projects 2010 “European Research Projects on Mental Disorders” 6. Brief CV for each group leader (max. 1 page per partner): Brief CV for each group leader
including a description of the main domain of research and a list of the 5 most relevant publications.
Biographical Sketch Prof. Dr. Julia Stingl (formerly Kirchheiner)
Date of Birth:

Place of Birth:

University Education:

University Erlangen-Nürnberg school of Chemistry University of Frankfurt/Main Medical school
Doctor of Medicine, University of Frankfurt/Main Medical School, Frankfurt, Germany Private Dozent (Habilitation), Charité University medicine, Berlin, Germany Professor of Clinical Pharmacology, University of Ulm Professor of Translational Pharmacology, Medical Faculty University Bonn Board Certification:

Professional Experience:
Residency in Psychiatry, Psychiatric university hospital, Freie Universität Berlin, Berlin, Germany (Prof. H. Helmchen) Training in Clinical Pharmacology, Charité University Medicine, Berlin, Germany (Prof. I. Roots) Scientific postdoctoral fellow, Department of Pharmacology, University of Cologne, Köln, Germany (Prof. E. Schömig) Professor of Clinical Pharmacology, Department of Natural Medicine and Clinical Pharmacology, University of Ulm, Germany Research sabbatical at the Office of Clinical Pharmacology, Centre for Drug Evaluation and Research, Food and Drug Administration, Washington, US Professor and director of the division of research, Federal Institute for Drugs and Medical devices, Bonn, Germany Major scientific interests:
Pharmacogenetics of drug metabolizing enzymes, pharmacogenetic mechanisms involved in
psychotropic drug response and the translation of pharmacogenetic diagnostics into clinical
guidelines. In particular, drug metabolism in the brain and pharmacological neuroimaging for the study
of variation in central nervous drug effects and for individualized treatment of mental disorder.
5 Publications
1: Stingl JC, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. Mol Psychiatry. 2013 Mar;18(3):273-87. 2: Viviani R, Abler B, Seeringer A, Stingl JC. Effect of paroxetine and bupropion on human resting brain perfusion: an arterial spin labeling study. Neuroimage. 2012 Jul 16;61(4):773-9. Call for transnational research projects 2010 “European Research Projects on Mental Disorders” 3: Stingl JC, Esslinger C, Tost H, Bilek E, Kirsch P, Ohmle B, Viviani R, Walter H, Rietschel M, Meyer-Lindenberg A. Genetic variation in CYP2D6 impacts neural activation during cognitive tasks in humans. Neuroimage. 2012 Feb 1;59(3):2818-23. 4: Stingl JC, Viviani R. CYP2D6 in the brain: impact on suicidality. Clin Pharmacol Ther. 2011 5: Abler B, Seeringer A, Hartmann A, Grön G, Metzger C, Walter M, Stingl J. Neural correlates of antidepressant-related sexual dysfunction: a placebo-controlled fMRI study on healthy males under subchronic paroxetine and bupropion. Neuropsychopharmacology. 2011 Aug;36(9):1837-47.


Fourth national deafness sector summit

FOURTH NATIONAL DEAFNESS SECTOR SUMMIT SATURDAY, 20 MAY 2006 PACIFIC INTERNATIONAL HOTEL, PERTH NICOLE LAWDER : I will now hand over to Barry MacKinnon, chair of the Hearing Services Consultative Committee, the Chair of the Deafness Council of WA and Disability Services WA, who will chair the next session. BARRY MacKINNON : Thank you very much. It is my pleasure at the outset to


Viral Ion Channels/viroporins Viral Proteins that Enhance Membrane Permeability María Eugenia González and Luis Carrasco 1. Introduction During the infection of cells by animal viruses, membrane permeability is modified attwo different steps of the virus life cycle (Carrasco, 1995) (Figure 6.1). Initially, when thevirion enters cells, a number of different-sized molecules are able

Copyright © 2008-2018 All About Drugs